Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASC40 + Bevacizumab in Recurrent Glioblastoma
NCT05118776Phase 3Active, not recruiting
- Sponsor
- Ascletis Pharma Inc.
- Start
- Jan 2022
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in glioblastoma (GBM) comparing ASC40 + Bevacizumab with Placebo + Bevacizumab (2 arms). Primary endpoints: Progression-Free Survival at 6 months and Overall Survival at 10 months. Started Jan 2022; status: active, not recruiting.
02
Drugs
denifanstat
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05118776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05118776.